Given that SDG supplementation in the in vivo tumor study significantly decreased E0771 tumor growth and expression of several pro-proliferative and anti-apoptotic NF-κB target genes, including Bcl2a1a, Birc2, Birc3, Egfr2, and Xiap, we were surprised to find that the 10 μM ENL treatment in vitro inhibited E0771 cell viability by only 27%. The gene discussed is BIRC2; the disease is neoplasm.